Herpes vector-mediated gene transfer in the treatment of chronic pain

Molecular Therapy

Volumn 17, Issue 1, 2009, Pages 13-18

  Glorioso, Joseph C ^a   Fink, David J ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; BACLOFEN; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CYTOKINE; ENDOTHELIN; ENKEPHALIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETANERCEPT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; HERPESVIRUS VECTOR; HISTAMINE; INTERLEUKIN 10; INTERLEUKIN 4; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; PROENKEPHALIN; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; TYROSYLPROLYLPHENYLALANYLPHENYLALANINE AMIDE; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTISENSE THERAPY; BREATHING DISORDER; CANCER PAIN; CHRONIC PAIN; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CYSTALGIA; DERMATOME; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; REVIEW; SENSORY NERVE CELL; SOMNOLENCE; TRANSGENE; URINE RETENTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS MUTATION; VISCERAL PAIN;

CHRONIC DISEASE; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; PAIN;

HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 58149242267     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.213     Document Type: Review

References (54)

1. Merskey, H, Albe-Fessard, D, Bonica, JJ, Carmon, A, Dubner, R, Kerr, FWL et al. (1979). Pain terms: A list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 6 249-252.
2. Niv, D and Devor, M (2004). Chronic pain as a disease in its own right. Pain Pract 4: 179-181.
3. Roizman, B and Knipe, DM (2001). Herpes simplex viruses and their replication. In: Knipe, DM and Howley, PM (eds). Fields Virology. Lippincott Williams & Wilkins: Philadelphia, PA. pp. 2399-2460.
4. DeLuca, NA, McCarthy, AM and Schaffer, PA (1985). Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 56: 558-570.
5. Wolfe, D, Goins, WF, Yamada, M, Moriuchi, S, Krisky, DM, Oligino, TJ et al. (1999). Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 159: 34-46.
6. Antunes Bras, JM, Epstein, AL, Bourgoin, S, Hamon, M, Cesselin, F and Pohl, M (1998). Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 70 1299-1303.
7. Wilson, SP, Yeomans, DC, Bender, MA, Lu, Y, Goins, WF and Glorioso, JC (1999). Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 96: 3211-3216.
8. Braz, J, Beaufour, C, Coutaux, A, Epstein, AL, Cesselin, F, Hamon, M et al. (2001). Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 21: 7881-7888.
9. Antunes bras, J, Becker, C, Bourgoin, S, Lombard, M, Cesselin, F, Hamon, M et al. (2001). Met-enkephalin is preferentially transported into the peripheral processes of primary afferent fibres in both control and HSV1-driven proenkephalin A overexpressing rats. Neuroscience 103: 1073-1083.
10. Goss, JR, Mata, M, Goins, WF, Wu, HH, Glorioso, JC and Fink, DJ (2001). Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 8: 551-556.
11. Hao, S, Mata, M, Goins, W, Glorioso, JC and Fink, DJ (2003). Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. Pain 102: 135-142.
12. Meunier, A, Latremoliere, A, Mauborgne, A, Bourgoin, S, Kayser, V, Cesselin, F et al. (2005). Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther 11: 608-616.
13. Goins, WF, Yoshimura, N, Phelan, MW, Yokoyama, T, Fraser, MO, Ozawa, H et al. (2001). Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: Potential treatment for diabetic bladder dysfunction. J Urol 165: 1748-1754.
14. Yoshimura, N, Franks, ME, Sasaki, K, Goins, WF, Goss, J, Yokoyama, T et al. (2001). Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology 57 6 (suppl. 1): 116.
15. Lu, Y, McNearney, TA, Lin, W, Wilson, SP, Yeomans, DC and Westlund, KN (2007). Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol Ther 15: 1812-1819.
16. Yang, H, McNearney, TA, Chu, R, Lu, Y, Ren, Y, Yeomans, DC et al. (2008). Enkephalin-encoding herpes simplex virus-1 decreases inflammation and hotplate sensitivity in a chronic pancreatitis model. Mol Pain 4: 8.
17. Honore, P, Rogers, SD, Schwei, MJ, Salak-Johnson, JL, Luger, NM, Sabino, MC et al. (2000). Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98: 585-598.
18. Goss, JR, Harley, CF, Mata, M, O'Malley, ME, Goins, WF, Hu, X et al. (2002). Herpes vector-mediated expression of proenkephalin reduces pain-related behavior in a model of bone cancer pain. Ann Neurol 52: 662-665.
19. Yeomans, DC, Lu, Y, Laurito, CE, Peters, MC, Vota-Vellis, G, Wilson, SP et al. (2006). Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol Ther 13: 589-597.
20. Zadina, JE, Hackler, L, Ge, LJ and Kastin, AJ (1997). A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386: 499-502.
21. Wolfe, D, Hao, S, Hu, J, Srinivasan, R, Goss, J, Mata, M et al. (2007). Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 133: 29-38.
22. Hao, S, Wolfe, D, Glorioso, JC, Mata, M and Fink, DJ (2008). Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain (epub ahead of print).
23. Jones, TL, Sweitzer, SM, Wilson, SP and Yeomans, DC (2003). Afferent fiber-selective shift in opiate potency following targeted opioid receptor knockdown. Pain 106: 365-371.
24. Zhang, G, Mohammad, H, Peper, BD, Raja, S, Wilson, SP and Sweitzer, SM (2008). Enhanced peripheral analgesia using virally mediated gene transfer of the mu-opioid receptor in mice. Anesthesiology 108 305-313.
25. Liu, J, Wolfe, D, Hao, S, Huang, S, Glorioso, JC, Mata, M et al. (2004). Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 10: 57-66.
26. Hao, S, Mata, M, Wolfe, D, Glorioso, JC and Fink, DJ (2005). Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 57: 914-918.
27. Moore, KA, Kohno, T, Karchewski, LA, Scholz, J, Baba, H and Woolf, CJ (2002). Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 22: 6724-6731.
28. DeLeo, JA and Yezierski, RP (2001). The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1-6.
29. Watkins, LR, Milligan, ED and Maier, SF (2001). Glial activation: A driving force for pathological pain. Trends Neurosci 24: 450-455.
30. Wieseler-Frank, J, Maier, SF and Watkins, LR (2004). Glial activation and pathological pain. Neurochem Int 45: 389-395.
31. DeLeo, JA, Tanga, FY and Tawfik, VL (2004). Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 10: 40-52.
32. Sommer, C, Schmidt, C and George, A (1998). Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 151 138-142.
33. Schafers, M, Svensson, CI, Sommer, C and Sorkin, LS (2003). Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23: 2517-2521.
34. Svensson, CI, Schafers, M, Jones, TL, Powell, H and Sorkin, LS (2005). Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett 379: 209-213.
35. Hao, S, Mata, M, Glorioso, JC and Fink, DJ (2007). Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 14: 1010-1016.
36. Peng, X, Zhou, Z, Glorioso, JC, Fink, DJ and Mata, M (2006). Tumor necrosis factor alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol 59: 843-851.
37. te Velde, AA, Huijbens, RJ, Heije, K, de Vries, JE and Figdor, CG (1990). Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood 76 1392-1397.
38. Mijatovic, T, Kruys, V, Caput, D, Defrance, P and Huez, G (1997). Interleukin-4 and -13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages. J Biol Chem 272: 14394-14398.
39. Poliani, PL, Brok, H, Furlan, R, Ruffini, F, Bergami, A, Desina, G et al. (2001). Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 12: 905-920.
40. Hao, S, Mata, M, Glorioso, JC and Fink, DJ (2006). HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain 2: 6.
41. Zhou, Z, Peng, X, Hao, S, Fink, DJ and Mata, M (2008). HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther 15: 183-190.
42. Bennett, DL, Boucher, TJ, Armanini, MP, Poulsen, KT, Michael, GJ, Priestley, JV et al. (2000). The glial cell line-derived neurotrophic factor family receptor components are differentially regulated within sensory neurons after nerve injury. J Neurosci 20: 427-437.
43. Hao, S, Mata, M, Wolfe, D, Huang, S, Glorioso, J and Fink, DJ (2003). HSV-mediated gene transfer of the glial cell derived neurotrophic factor (GDNF) provides an anti-allodynic effect in neuropathic pain. Mol Ther 8: 367-375.
44. Yeomans, DC, Levinson, SR, Peters, MC, Koszowski, AG, Tzabazis, AZ, Gilly, WF et al. (2005). Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther 16: 271-277.
45. Tzabazis, AZ, Pirc, G, Votta-Velis, E, Wilson, SP, Laurito, CE, Yeomans, DC (2007). Antihyperalgesic effect of a recombinant herpes virus encoding antisense for calcitonin gene-related peptide. Anesthesiology 106: 1196-1203.
46. Srinivasan, R, Huang, S, Chaudhry, S, Sculptoreanu, A, Krisky, D, Cascio, M et al. (2007). An HSV vector system for selection of ligand-gated ion channel modulators. Nat Methods 4: 733-739.
47. Srinivasan, R, Wolfe, D, Goss, J, Watkins, S, de Groat, W, Sculptoreanu, A et al. (2008). PKCε contributes to basal and sensitizing responses of Trpv1 to capsaicin in dorsal root ganglion neurons. Eur J pain (in the press).
48. v1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci 28: 6652-6658.
49. Goins, WF, Sternberg, LR, Croen, KD, Krause, PR, Hendricks, RL, Fink, DJ et al. (1994). A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol 68 2239-2252.
50. Puskovic, V, Wolfe, D, Goss, J, Huang, S, Mata, M, Glorioso, JC et al. (2004). Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther 10: 67-75.
51. Chattopadhyay, M, Mata, M, Goss, J, Wolfe, D, Huang, S, Glorioso, JC et al. (2007). Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia 50: 1550-1558.
52. Chattopadhyay, M, Wolfe, D, Mata, M, Huang, S, Glorioso, JC and Fink, DJ (2005). Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther 12: 307-313.
53. Shand, N, Weber, F, Mariani, L, Bernstein, M, Gianella-Borradori, A, Long, Z et al. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10: 2325-2335.
54. Rainov, NG (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389-2401.